| | | | | | | | When it comes to aging, pharmacologic interventions have mostly been limited to treating the symptoms of one chronic disease at a time. But many young biotechs have stepped up to the forefront of innovation, offering technology platforms that have produced compelling preclinical research that has the potential to slow the sands of time. The result is a longevity market on the brink of coming into its own. |
|
|
|
| |
| | |
|
|
| | | | | Ongoing demand and manufacturing capacity issues will drive European shortages into late 2024. |
|
|
| The drugmaker has signed a multi-year, $1B deal with Switzerland-based startup Haya Therapeutics to identify RNA-based drug targets in obesity and metabolic conditions. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | Supply chain challenges have long been a reality for pharma manufacturers, but the pandemic underscored the critical need for enhanced visibility and control. Added pressures, such as drug shortages and geopolitical unrest, mean that pharma must focus on creating a supply chain that is truly sustainable... |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
